Chronic hand eczema remains a persistent and often debilitating skin condition affecting millions worldwide, characterized by inflammation, redness, itching, and cracking of the hands that can significantly impair daily functioning and quality of life. For many patients, prolonged use of topical corticosteroids—the traditional first-line treatment—carries risks of skin atrophy, telangiectasia, and reduced efficacy over time, creating a pressing need for alternative therapeutic options with improved safety profiles for long-term management.
Recent clinical evidence highlights topical delgocitinib as a promising advancement in this space, demonstrating consistent and statistically significant improvement in symptoms after 16 weeks of treatment across multiple rigorous trials. As a selective Janus kinase (JAK) inhibitor formulated for topical application, delgocitinib works by modulating key inflammatory pathways involved in eczema pathogenesis without the systemic exposure associated with oral JAK inhibitors, offering a targeted approach to skin-directed therapy.
Regulatory milestones underscore the growing recognition of this treatment option, with the European Medicines Agency granting approval in 2024 and the U.S. Food and Drug Administration following suit in 2025 specifically for the management of chronic hand eczema in adults. These authorizations were based on data from three pivotal Phase 3 trials involving over 1,100 patients, which collectively showed that a significantly higher proportion of patients achieved treatment success—defined as clear or almost clear skin with minimal residual symptoms—compared to vehicle control at the 16-week endpoint.
Beyond primary efficacy endpoints, secondary analyses from these studies revealed meaningful improvements in patient-reported outcomes, including reductions in itch intensity and improvements in health-related quality of life measures, reinforcing the clinical relevance of the observed skin clearance. Safety profiles remained favorable throughout the trials, with most adverse events being mild to moderate and localized to the application site, such as transient application site pain or erythema, and no new safety signals emerged beyond those already characterized in the drug’s development program.
The mechanism of action of delgocitinib centers on its inhibition of JAK1, JAK2, JAK3, and TYK2 kinases—key enzymes in the signaling cascade of cytokines implicated in inflammatory skin diseases like eczema. By blocking these intracellular signals, the drug helps reduce the release of pro-inflammatory mediators, thereby alleviating the epidermal hyperplasia, spongiosis, and immune cell infiltration that drive the visible and symptomatic manifestations of chronic hand eczema. Its topical formulation ensures high concentrations in the skin although minimizing systemic absorption, a critical factor in maintaining a favorable benefit-risk ratio for chronic use.
Patient advocacy groups and dermatology organizations have welcomed these developments, noting that chronic hand eczema disproportionately affects individuals in occupations involving frequent hand washing, exposure to irritants, or mechanical stress—such as healthcare workers, cleaners, food handlers, and those in manufacturing or construction—making effective, safe long-term options particularly valuable for workforce participation and occupational health.
Ongoing research continues to explore the potential of delgocitinib in other inflammatory skin conditions, including atopic dermatitis and psoriasis, though current regulatory approvals remain specific to chronic hand eczema. Healthcare providers are advised to consult official prescribing information for detailed guidance on dosage, administration, and monitoring, with treatment typically involving twice-daily application to affected areas for up to 16 weeks, as evaluated in the pivotal trials.
As the medical community gains more real-world experience with this therapy, post-marketing surveillance and real-world evidence studies will play an important role in further characterizing its long-term safety and effectiveness across diverse patient populations. For now, the availability of a non-steroidal, topical JAK inhibitor represents a meaningful addition to the therapeutic arsenal for a condition that has historically posed significant challenges in management.
The next major milestone in the lifecycle of delgocitinib for chronic hand eczema will be the submission of periodic safety update reports to regulatory authorities, with the first such report expected within one year of the FDA’s 2025 approval, providing updated safety data from broader clinical use.
If you or someone you know is managing chronic hand eczema, consult a dermatologist or healthcare provider to discuss whether emerging treatments like topical delgocitinib may be appropriate based on individual medical history and treatment goals. Share your experiences or questions in the comments below to help foster informed conversations within the patient community.